- Home
- PNST vs RLMD Comparison
PNST vs RLMD Comparison
Compare PNST & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNST
- RLMD
- Stock Information
- Founded
- PNST 2007
- RLMD 2004
- Country
- PNST United States
- RLMD United States
- Employees
- PNST N/A
- RLMD N/A
- Industry
- PNST Blank Checks
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- PNST Finance
- RLMD Health Care
- Exchange
- PNST Nasdaq
- RLMD Nasdaq
- Market Cap
- PNST 14.2M
- RLMD 11.5M
- IPO Year
- PNST N/A
- RLMD N/A
- Fundamental
- Price
- PNST $0.35
- RLMD $0.37
- Analyst Decision
- PNST Strong Buy
- RLMD Hold
- Analyst Count
- PNST 3
- RLMD 4
- Target Price
- PNST $2.50
- RLMD $4.25
- AVG Volume (30 Days)
- PNST 198.1K
- RLMD 942.1K
- Earning Date
- PNST 02-19-2025
- RLMD 03-18-2025
- Dividend Yield
- PNST N/A
- RLMD N/A
- EPS Growth
- PNST N/A
- RLMD N/A
- EPS
- PNST N/A
- RLMD N/A
- Revenue
- PNST $123,579,000.00
- RLMD N/A
- Revenue This Year
- PNST $16.07
- RLMD N/A
- Revenue Next Year
- PNST $19.19
- RLMD N/A
- P/E Ratio
- PNST N/A
- RLMD N/A
- Revenue Growth
- PNST 11.06
- RLMD N/A
- 52 Week Low
- PNST $0.34
- RLMD $0.34
- 52 Week High
- PNST $4.92
- RLMD $7.22
- Technical
- Relative Strength Index (RSI)
- PNST 31.54
- RLMD 25.62
- Support Level
- PNST $0.34
- RLMD $0.36
- Resistance Level
- PNST $0.45
- RLMD $0.49
- Average True Range (ATR)
- PNST 0.05
- RLMD 0.06
- MACD
- PNST 0.00
- RLMD 0.08
- Stochastic Oscillator
- PNST 9.29
- RLMD 10.06
About PNST Pinstripes Holdings Inc.
Pinstripes Holdings Inc is an experiential dining and entertainment concept combining exceptional Italian-American cuisine with bowling, bocce, and private events. It owns and operates around 17 restaurants in the USA. The company designs and constructs large-format locations that are each 26,000 to 38,000 square feet of interior space, plus additional outdoor patio space that includes outdoor dining, bocce courts, fire-pits, and decorative fountains.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.